ABVC Biopharma Inc - Asset Resilience Ratio
ABVC Biopharma Inc (ABVC) has an Asset Resilience Ratio of 0.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how ABVC Biopharma Inc's Asset Resilience Ratio has changed over time. Check ABVC capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down ABVC Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABVC Biopharma Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.19K | 0.32% |
| Total Liquid Assets | $62.19K | 0.32% |
Asset Resilience Insights
- Limited Liquidity: ABVC Biopharma Inc maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ABVC Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare ABVC Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for ABVC Biopharma Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for ABVC Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.31% | $64.35K | $21.06 Million | -0.55pp |
| 2024-12-31 | 0.86% | $64.74K | $7.54 Million | -0.16pp |
| 2023-12-31 | 1.02% | $79.31K | $7.78 Million | +0.33pp |
| 2022-12-31 | 0.69% | $75.80K | $10.93 Million | -0.10pp |
| 2021-12-31 | 0.79% | $108.15K | $13.70 Million | -7.27pp |
| 2020-12-31 | 8.06% | $1.19 Million | $14.77 Million | -40.50pp |
| 2019-12-31 | 48.57% | $3.36 Million | $6.93 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $6.60 Million | -- |
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more